glp-1 shortage news today november 2025 The class of medicines known as GLP-1s have transformed clinical practice and shifted public perception to view obesity as a chronic disease that merits medical management. Growing research is demonstrating that the What's next for GLP-1 innovation:

That is close to an eleven-fold spread for the same medications

Absolute muscle cross-sectional area of the vastus lateralis decreased significantly

Ascendis Pharma A/S granted Novo Nordisk A/S exclusive global rights to its TransCon technology for the development, manufacturing, and commercialisation of Novo Nordisk products aimed at metabolic diseases, including obesity and type 2 diabetes, along with select cardiovascular applications

Incomplete reduction of oxygen in hypoxic condition results in elevated production of superoxide and hydroxyl radicals

It is not peer-reviewed, it is not laboratory data, and it should not appear in a methods section or a literature review